Complement Inhibitors as DMOADs
作为 DMOAD 的补体抑制剂
基本信息
- 批准号:8730337
- 负责人:
- 金额:$ 7.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-15 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcetaminophenAdolescentAdrenal Cortex HormonesAffectAgeAge-MonthsAlternative Complement PathwayAnalgesicsAnterior Cruciate LigamentAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAreaArthritisBolus InfusionCartilageCategoriesCell Culture TechniquesChronicClinicClinical TrialsComplementComplement 3aComplement 5aComplement Factor BComplement InactivatorsComplexCoupledDataDegenerative polyarthritisDevelopmentDiagnostic radiologic examinationDiseaseDisease ManagementDisease ProgressionDoseDrug KineticsEffectivenessElderlyEtiologyEvaluationFeedbackFunctional disorderHistologyHost DefenseHumanHumanitiesHyaluronic AcidIL8 geneIbuprofenIgG1IndomethacinInflammation MediatorsInflammatoryInjection of therapeutic agentInterleukin-12Interleukin-17Interleukin-6InvestigationJointsKnockout MiceLegal patentMammalian CellMediatingMessenger RNAModelingMonitorMonoclonal AntibodiesMusNaproxenOpiatesOryctolagus cuniculusPainPathway interactionsPatientsPharmaceutical PreparationsPhasePlayPopulationPreparationPrevalenceProcessProductionProperdinProteinsProtocols documentationQuality of lifeRegimenResearchRoleRouteSwellingSymptomsSynovial FluidTNF geneTestingTherapeuticTherapeutic AgentsTherapeutic antibodiesTimeTissuesUnited States National Institutes of HealthVariantWorkagedarthropathiesbone losscelecoxibcomplement systemcost effectivecyclooxygenase 2cytokinedisabilityetoricoxibexperiencehumanized antibodyhumanized monoclonal antibodiesimprovedinhibiting antibodyinhibitor/antagonistinnovationinsightjoint injuryneutralizing antibodynovelpreventscale upsoluble complement C5b-9success
项目摘要
DESCRIPTION (provided by applicant): Complement system play a role in preventing inflammation and joint immobility. Osteoarthritis (OA), an inflammatory disease of the joints, is quite prevalent among the elderly and causes disability in nearly 10% of the population over 55 years. Current medications only manage the disease and do not cure or halt the disease. The prevalence of OA coupled with the absence of Disease Modifying Osteoarthritis Drugs (DMOADs) heightens the negative impact of this disease on humanity. Recent studies have shown that cytokines are important in the development and progression of OA. It has been hypothesized that neutralizing IL-12 or TNF-1 may provide benefit to OA patients, hence, biologics or drugs that neutralize these cytokines are being investigated. Clinical trials with an anti-TNF-1 antibody are currently ongoing. The alternative pathway (AP) of complement has recently been implicated in the etiology of OA. We have developed a proprietary group of antibodies that selectively target the AP without affecting the host defense mediated via the classical pathway (CP). Our preliminary results suggest that the AP plays an important role in the development and progression of OA and that our target antibody is highly effective in resolving OA as indicated by rabbit models of OA. The current application proposes development of a humanized IgG1 as a potent treatment for halting and arresting the progression of OA in humans. In the Phase I segment, we further test a specific neutralizing anti-complement monoclonal antibody in the young rabbit OA model. In the Phase II segment, we will study the efficacy of the targeted humanized antibody to aged rabbits, evaluate the efficacy of the biologic in multiple modes of administration, and establish protocol for scaled up preparation of the humanized antibody. Our studies will provide new insight into the development of novel therapies for the treatment of OA. Overall, the proposed work is a critical step in the direction of developing a cost-effective, efficacious and safe therapeutic agent for preventing joint damage caused by OA.
说明(申请人提供):补体系统起到预防炎症和关节不动的作用。骨关节炎(OA)是一种关节炎症性疾病,在老年人中相当普遍,在55岁以上的人口中导致近10%的人残疾。目前的药物只能治疗这种疾病,而不能治愈或阻止这种疾病。骨性关节炎的流行,加上缺乏治疗疾病的骨关节炎药物(DMOADs),加剧了这种疾病对人类的负面影响。最近的研究表明,细胞因子在骨性关节炎的发生发展中起着重要作用。据推测,中和IL-12或肿瘤坏死因子-1可能对骨关节炎患者有好处,因此,中和这些细胞因子的生物制剂或药物正在研究中。抗肿瘤坏死因子-1抗体的临床试验目前正在进行中。补体的替代途径(AP)最近被认为与骨性关节炎的病因有关。我们已经开发了一组专有的抗体,这些抗体可以选择性地针对AP,而不会影响通过经典途径(CP)介导的宿主防御。我们的初步结果表明,AP在OA的发生和发展中起着重要作用,并且我们的靶抗体在解决OA方面是高效的,正如兔OA模型所表明的那样。目前的应用建议开发人源化的IgG1作为一种有效的治疗方法来阻止和阻止人类骨性关节炎的进展。在I相片段中,我们进一步在幼兔OA模型中检测了一种特异性的中和抗补体单抗。在第二阶段,我们将研究靶向人源化抗体对老龄兔的效果,评价多种给药模式下的生物效果,并建立放大制备人源化抗体的方案。我们的研究将为开发治疗骨性关节炎的新疗法提供新的见解。总体而言,拟议的工作是朝着开发成本效益高、有效和安全的治疗药物的方向迈出的关键一步,以防止骨关节炎造成的关节损害。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rekha Bansal其他文献
Rekha Bansal的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rekha Bansal', 18)}}的其他基金
Disease Modifying Treatment for Hemolytic Disorders
溶血性疾病的疾病修饰治疗
- 批准号:
10254750 - 财政年份:2021
- 资助金额:
$ 7.88万 - 项目类别:
Preclinical and Clinical Evaluation of Humanized NM9405
人源化NM9405的临床前和临床评价
- 批准号:
8647587 - 财政年份:2014
- 资助金额:
$ 7.88万 - 项目类别:
Preclinical and Clinical Evaluation of Humanized NM9405
人源化NM9405的临床前和临床评价
- 批准号:
8925257 - 财政年份:2014
- 资助金额:
$ 7.88万 - 项目类别:
Preclinical and Clinical Evaluation of Humanized NM9405
人源化NM9405的临床前和临床评价
- 批准号:
9038429 - 财政年份:2014
- 资助金额:
$ 7.88万 - 项目类别:
Alternative Pathway Inhibitors for Orphan Indication
用于孤儿适应症的替代途径抑制剂
- 批准号:
8524040 - 财政年份:2013
- 资助金额:
$ 7.88万 - 项目类别:
Alternative Pathway Inhibitors for Orphan Indication
用于孤儿适应症的替代途径抑制剂
- 批准号:
8883970 - 财政年份:2013
- 资助金额:
$ 7.88万 - 项目类别:
相似海外基金
Exploring the mental health and wellbeing of adolescent parent families affected by HIV in South Africa
探讨南非受艾滋病毒影响的青少年父母家庭的心理健康和福祉
- 批准号:
ES/Y00860X/1 - 财政年份:2024
- 资助金额:
$ 7.88万 - 项目类别:
Fellowship
Scaling-up co-designed adolescent mental health interventions
扩大共同设计的青少年心理健康干预措施
- 批准号:
MR/Y020286/1 - 财政年份:2024
- 资助金额:
$ 7.88万 - 项目类别:
Fellowship
Shared Spaces: The How, When, and Why of Adolescent Intergroup Interactions
共享空间:青少年群体间互动的方式、时间和原因
- 批准号:
ES/T014709/2 - 财政年份:2024
- 资助金额:
$ 7.88万 - 项目类别:
Research Grant
Social Media Mechanisms Affecting Adolescent Mental Health (SoMe3)
影响青少年心理健康的社交媒体机制 (SoMe3)
- 批准号:
MR/X034925/1 - 财政年份:2024
- 资助金额:
$ 7.88万 - 项目类别:
Fellowship
Parent-adolescent informant discrepancies: Predicting suicide risk and treatment outcomes
父母与青少年信息差异:预测自杀风险和治疗结果
- 批准号:
10751263 - 财政年份:2024
- 资助金额:
$ 7.88万 - 项目类别:
The Impact of Online Social Interactions on Adolescent Cognition
在线社交互动对青少年认知的影响
- 批准号:
DE240101039 - 财政年份:2024
- 资助金额:
$ 7.88万 - 项目类别:
Discovery Early Career Researcher Award
Adolescent sugar overconsumption programs food choices via altered dopamine signalling
青少年糖过度消费通过改变多巴胺信号来影响食物选择
- 批准号:
BB/Y006496/1 - 财政年份:2024
- 资助金额:
$ 7.88万 - 项目类别:
Research Grant
Resilience Factors, Pain, and Physical Activity in Adolescent Chronic Musculoskeletal Pain
青少年慢性肌肉骨骼疼痛的弹性因素、疼痛和体力活动
- 批准号:
10984668 - 财政年份:2024
- 资助金额:
$ 7.88万 - 项目类别:
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 7.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluating the impact of changes in the proximity and density of vape retailers around secondary schools in Ontario on adolescent vaping behaviours
评估安大略省中学周围电子烟零售商的距离和密度变化对青少年电子烟行为的影响
- 批准号:
500515 - 财政年份:2023
- 资助金额:
$ 7.88万 - 项目类别:
Operating Grants